WO2004071419A3 - Methods and compositions for modulating glutamate transport activity in the nervous system - Google Patents

Methods and compositions for modulating glutamate transport activity in the nervous system Download PDF

Info

Publication number
WO2004071419A3
WO2004071419A3 PCT/US2004/003228 US2004003228W WO2004071419A3 WO 2004071419 A3 WO2004071419 A3 WO 2004071419A3 US 2004003228 W US2004003228 W US 2004003228W WO 2004071419 A3 WO2004071419 A3 WO 2004071419A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
transport activity
nervous system
glutamate transport
Prior art date
Application number
PCT/US2004/003228
Other languages
French (fr)
Other versions
WO2004071419A2 (en
Inventor
Davide Trotti
Robert H Brown
Original Assignee
Gen Hospital Corp
Davide Trotti
Robert H Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Davide Trotti, Robert H Brown filed Critical Gen Hospital Corp
Priority to CA002488143A priority Critical patent/CA2488143A1/en
Publication of WO2004071419A2 publication Critical patent/WO2004071419A2/en
Publication of WO2004071419A3 publication Critical patent/WO2004071419A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to products and methods for modulating glutamate transport activity and reducing glutamate excitotoxicity. The methods of the invention are useful to prevent and treat glutamate excitotoxicity-associated neurological disorders.
PCT/US2004/003228 2003-02-07 2004-02-05 Methods and compositions for modulating glutamate transport activity in the nervous system WO2004071419A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002488143A CA2488143A1 (en) 2003-02-07 2004-02-05 Methods and compositions for modulating glutamate transport activity in the nervous system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44606203P 2003-02-07 2003-02-07
US60/446,062 2003-02-07

Publications (2)

Publication Number Publication Date
WO2004071419A2 WO2004071419A2 (en) 2004-08-26
WO2004071419A3 true WO2004071419A3 (en) 2006-06-22

Family

ID=32869450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003228 WO2004071419A2 (en) 2003-02-07 2004-02-05 Methods and compositions for modulating glutamate transport activity in the nervous system

Country Status (2)

Country Link
CA (1) CA2488143A1 (en)
WO (1) WO2004071419A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100679306B1 (en) * 2005-03-31 2007-02-06 아미코젠주식회사 Pharmaceutical composition for treating or preventing a neurological brain disease comprising lignan compounds
ES2389566T3 (en) 2005-05-17 2012-10-29 Santen Pharmaceutical Co., Ltd. Preventive or therapeutic agent to treat a corneal and conjunctiva disorder
GB0721616D0 (en) * 2007-11-02 2007-12-12 Queen Mary & Westfield College Treatment of spinal cord injury
KR20100124756A (en) 2008-02-28 2010-11-29 산텐 세이야꾸 가부시키가이샤 Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder
EP2919816B1 (en) * 2012-11-14 2019-03-27 Daniel Offen Combination treatment for amyotrophic lateral sclerosis (als)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098473A1 (en) * 2000-07-25 2002-07-25 Edwards Robert H. Novel glutamate transporters
US20030050224A1 (en) * 2001-08-20 2003-03-13 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
US6808893B1 (en) * 1999-10-23 2004-10-26 The Johns Hopkins University School Of Medicine Glutamate transporter associated proteins and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808893B1 (en) * 1999-10-23 2004-10-26 The Johns Hopkins University School Of Medicine Glutamate transporter associated proteins and methods of use thereof
US20020098473A1 (en) * 2000-07-25 2002-07-25 Edwards Robert H. Novel glutamate transporters
US20030050224A1 (en) * 2001-08-20 2003-03-13 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases

Also Published As

Publication number Publication date
CA2488143A1 (en) 2004-08-26
WO2004071419A2 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
EP1471909A4 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2006044825A3 (en) Mitotic kinesin inhibitors and methods of use thereof
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
WO2004108133A3 (en) Modulators of vr1 receptor
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
WO2005065183A3 (en) Mitotic kinesin inhibitors
IL186707A (en) Mitotic kinesin inhibitors and pharmaceutical compostions comprising them
EP1802321A4 (en) Compositions and methods for modulating pgc-1-alpha to treat neurological diseases and disorders
WO2004071419A3 (en) Methods and compositions for modulating glutamate transport activity in the nervous system
WO2006011136A3 (en) Novel naphthoquinone derivatives and uses thereof
WO2005060654A3 (en) Mitotic kinesin inhibitors
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
AU2003290970A1 (en) Compositions and method for treating affective, painful or allergic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2488143

Country of ref document: CA

122 Ep: pct application non-entry in european phase